Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Phosphoinositide 3-kinase inhibitors in lymphoma.

Curran E, Smith SM.

Curr Opin Oncol. 2014 Sep;26(5):469-75. doi: 10.1097/CCO.0000000000000113. Review.

2.

The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.

Seiler T, Hutter G, Dreyling M.

Drugs. 2016 Apr;76(6):639-46. doi: 10.1007/s40265-016-0565-4. Review.

PMID:
27052260
3.

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.

Jabbour E, Ottmann OG, Deininger M, Hochhaus A.

Haematologica. 2014 Jan;99(1):7-18. doi: 10.3324/haematol.2013.087171. Review.

4.

Idelalisib in the management of lymphoma.

Cheah CY, Fowler NH.

Blood. 2016 Jul 21;128(3):331-6. doi: 10.1182/blood-2016-02-702761. Epub 2016 Jun 1. Review.

5.

PI3 kinase inhibitors in the clinic: an update.

Kurtz JE, Ray-Coquard I.

Anticancer Res. 2012 Jul;32(7):2463-70. Review.

PMID:
22753702
6.

Target of rapamycin signaling in leukemia and lymphoma.

Vu C, Fruman DA.

Clin Cancer Res. 2010 Nov 15;16(22):5374-80. doi: 10.1158/1078-0432.CCR-10-0480. Epub 2010 Sep 8. Review.

7.

Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.

Beck JT, Ismail A, Tolomeo C.

Cancer Treat Rev. 2014 Sep;40(8):980-9. doi: 10.1016/j.ctrv.2014.06.006. Epub 2014 Jul 3. Review.

PMID:
25037117
8.

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman DA, Honig B, Landry DW, O'Connor OA.

Blood. 2017 Jan 5;129(1):88-99. doi: 10.1182/blood-2016-08-731240. Epub 2016 Oct 26.

9.

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

Westin JR.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):335-42. doi: 10.1016/j.clml.2014.01.007. Epub 2014 Feb 7. Review.

10.

PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.

Wang X, Ding J, Meng LH.

Acta Pharmacol Sin. 2015 Oct;36(10):1170-6. doi: 10.1038/aps.2015.71. Epub 2015 Sep 14. Review.

11.

Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.

Blachly JS, Baiocchi RA.

Br J Haematol. 2014 Oct;167(1):19-32. doi: 10.1111/bjh.13065. Epub 2014 Aug 6. Review.

PMID:
25100567
12.

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Wu P, Hu YZ.

Curr Med Chem. 2010;17(35):4326-41. Review.

PMID:
20939811
13.

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?

Zardavas D, Fumagalli D, Loi S.

Curr Opin Oncol. 2012 Nov;24(6):623-34. doi: 10.1097/CCO.0b013e328358a2b5. Review.

PMID:
22960556
14.

Targeting PI3 kinase in cancer.

Bauer TM, Patel MR, Infante JR.

Pharmacol Ther. 2015 Feb;146:53-60. doi: 10.1016/j.pharmthera.2014.09.006. Epub 2014 Sep 18. Review.

PMID:
25240910
15.

PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.

Furukawa S, Wei L, Krams SM, Esquivel CO, Martinez OM.

Am J Transplant. 2013 Aug;13(8):2035-43. doi: 10.1111/ajt.12328. Epub 2013 Jul 10.

16.

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.

Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.

Cancer Res. 2009 Apr 15;69(8):3520-8. doi: 10.1158/0008-5472.CAN-08-4884. Epub 2009 Apr 7.

17.

Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.

Kashiyama T, Oda K, Ikeda Y, Shiose Y, Hirota Y, Inaba K, Makii C, Kurikawa R, Miyasaka A, Koso T, Fukuda T, Tanikawa M, Shoji K, Sone K, Arimoto T, Wada-Hiraike O, Kawana K, Nakagawa S, Matsuda K, McCormick F, Aburatani H, Yano T, Osuga Y, Fujii T.

PLoS One. 2014 Feb 4;9(2):e87220. doi: 10.1371/journal.pone.0087220. eCollection 2014.

18.

Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.

Chen Y, Zhang L, Yang C, Han J, Wang C, Zheng C, Zhou Y, Lv J, Song Y, Zhu J.

Bioorg Med Chem. 2016 Mar 1;24(5):957-66. doi: 10.1016/j.bmc.2016.01.008. Epub 2016 Jan 6.

PMID:
26819001
19.

Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia.

Wang X, Zhang X, Li BS, Zhai X, Yang Z, Ding LX, Wang H, Liang C, Zhu W, Ding J, Meng LH.

Oncotarget. 2014 Nov 15;5(21):10732-44.

20.

Recent developments of small molecule PI3K/mTOR dual inhibitors.

Liu YN, Wan RZ, Liu ZP.

Mini Rev Med Chem. 2013 Dec;13(14):2047-59. Review.

PMID:
24195664

Supplemental Content

Support Center